The firm is the U.S.-based clinical development and research organization of a diversified global pharmaceutical company. The firm is actively seeking global partnering opportunities that complement its parent company’s therapeutic pipeline and long-term research priorities. Potential partnership structures include in-licensing, co-development, co-commercialization, and other strategic collaborations. While the firm has the capacity to make direct investments, its primary focus is on strategic partnerships rather than traditional venture capital investments.
The firm focuses on novel therapeutics addressing cardiovascular disease, metabolic disorders, peripheral arterial disease, and pain management. The firm is generally stage-agnostic and is particularly interested in compounds that can be advanced through clinical proof-of-concept. Although the firm’s historical expertise centers on small molecules, the firm is expanding its interest to include antibodies, cell therapies, and other emerging therapeutic modalities. The firm also has strong interest in innovative platform technologies with potential applications across multiple therapeutic programs.
From a company and management team perspective, the firm does not impose specific requirements regarding organizational structure, management experience, or company maturity. The firm seeks differentiated therapeutic assets and technologies with strong scientific rationale, compelling development potential, and strategic alignment with its broader pharmaceutical research and development capabilities.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
